Are Fund Managers Shunning European Biotech?
Executive Summary
Despite some recent successes, European biotech remains a less attractive investment opportunity than US biotech, according to most of the panel of European-based health care fund managers interviewed by In Vivo Europe Rx. But all is not lost: some running Europe-only, specialist funds continue to see value in the early stage small-caps.